0.00
price down icon100.00%   -0.3291
 
loading
Allakos Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
See More
Previous Close:
$0.3291
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$29.69M
Revenue:
-
Net Income/Loss:
$-166.14M
P/E Ratio:
0.00
EPS:
-1.92
Net Cash Flow:
$-139.92M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$1.555

Allakos Inc Stock (ALLK) Company Profile

Name
Name
Allakos Inc
Name
Phone
650-597-5002
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
2025-05-16
Name
Latest SEC Filings
Name
ALLK's Discussions on Twitter

Compare ALLK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALLK
Allakos Inc
0.00 29.69M 0 -166.14M -139.92M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.05 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
555.95 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.81 28.51B 3.81B -644.79M -669.77M -6.24

Allakos Inc Stock (ALLK) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-17-24 Downgrade Jefferies Buy → Hold
Jan-16-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-18-23 Upgrade William Blair Mkt Perform → Outperform
Dec-08-23 Resumed Jefferies Buy
Sep-27-23 Initiated JMP Securities Mkt Outperform
May-12-23 Upgrade Jefferies Hold → Buy
Mar-07-23 Initiated Piper Sandler Overweight
Sep-12-22 Downgrade SMBC Nikko Neutral → Underperform
Dec-22-21 Downgrade BofA Securities Buy → Underperform
Dec-22-21 Downgrade Cowen Outperform → Market Perform
Dec-22-21 Downgrade Jefferies Buy → Hold
Dec-22-21 Downgrade SVB Leerink Outperform → Mkt Perform
Dec-22-21 Downgrade William Blair Outperform → Mkt Perform
Aug-26-21 Initiated Morgan Stanley Equal-Weight
Jul-15-21 Initiated Cowen Outperform
May-18-21 Initiated H.C. Wainwright Buy
Feb-24-21 Initiated Cantor Fitzgerald Overweight
Jan-15-21 Initiated BofA Securities Buy
Dec-21-20 Initiated SVB Leerink Outperform
Feb-27-20 Initiated Barclays Underweight
Feb-04-20 Resumed Goldman Neutral
Aug-13-18 Initiated Goldman Neutral
Aug-13-18 Initiated Jefferies Buy
Aug-13-18 Initiated William Blair Outperform
View All

Allakos Inc Stock (ALLK) Latest News

pulisher
Jun 10, 2025

ALLKAllakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - mx.advfn.com

Jun 10, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Has $122,000 Stock Position in Allakos Inc. (NASDAQ:ALLK) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Allakos Inc. (NASDAQ:ALLK) Position Lowered by Millennium Management LLC - Defense World

Jun 08, 2025
pulisher
May 28, 2025

Allakos Inc. (NASDAQ:ALLK) Stock Holdings Lowered by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 23, 2025

TANG CAPITAL MANAGEMENT LLC Significantly Reduces Holdings in Al - GuruFocus

May 23, 2025
pulisher
May 23, 2025

TANG CAPITAL MANAGEMENT LLC Significantly Reduces Holdings in Allakos Inc - GuruFocus

May 23, 2025
pulisher
May 16, 2025

Allakos stock hits 52-week low at $0.3 amid market challenges - MSN

May 16, 2025
pulisher
May 16, 2025

Allakos completes merger with Concentra Biosciences By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 15, 2025

Allakos Completes Merger with Concentra Biosciences - TipRanks

May 15, 2025
pulisher
May 15, 2025

Allakos completes merger with Concentra Biosciences - Investing.com

May 15, 2025
pulisher
May 14, 2025

Allakos Inc.(NasdaqGS: ALLK) dropped from S&P TMI Index - marketscreener.com

May 14, 2025
pulisher
May 06, 2025

Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC - Defense World

May 06, 2025
pulisher
May 05, 2025

Allakos Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 01, 2025

ALLK Shares Experience Decline in Value - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

Renaissance Technologies LLC Has $1.02 Million Position in Allakos Inc. (NASDAQ:ALLK) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 28, 2025

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Apr 28, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 27, 2025

ALLK NOTICE: ROSEN, THE FIRST FILING FIRM, Reminds Allakos Inc. Investors of Important Deadline in Securities Class Action Seeking Recovery of Investor Losses; Those with Losses in Excess of $100K Should Contact FirmALLK - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 22, 2025

Checking in on Allakos Inc (ALLK) after recent insiders movement - knoxdaily.com

Apr 22, 2025
pulisher
Apr 04, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders - PR Newswire

Apr 04, 2025
pulisher
Apr 03, 2025

Allakos Inc (ALLK) Recovers 48.96% From Low: Are We There Yet? - stocksregister.com

Apr 03, 2025
pulisher
Apr 03, 2025

Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st

Apr 03, 2025
pulisher
Apr 03, 2025

Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 13.9% - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million. - marketscreener.com

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com

Apr 02, 2025
pulisher
Apr 02, 2025

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos agrees to Concentra Biosciences acquisition - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos surges on reverse merger deal with Concentra Biosciences - Seeking Alpha

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos to Be Acquired for 33 Cents a Share - MarketWatch

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - StreetInsider

Apr 02, 2025
pulisher
Apr 02, 2025

Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph

Apr 02, 2025
pulisher
Apr 02, 2025

Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire

Apr 01, 2025
pulisher
Mar 26, 2025

Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 24, 2025

Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Mar 24, 2025
pulisher
Mar 20, 2025

Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire

Mar 20, 2025

Allakos Inc Stock (ALLK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.01
price up icon 1.80%
$35.71
price down icon 0.18%
$22.83
price up icon 0.62%
$96.88
price down icon 0.67%
$111.47
price up icon 0.91%
biotechnology ONC
$243.50
price up icon 0.85%
Cap:     |  Volume (24h):